Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2962098 | 0.85 | SMN1; SMN2 (0.33) | SMN1; SMN2HTTKMT2AMAPTNR1H3 | |
| SCHEMBL3498324 | 0.83 | MAPT (0.33) | SMN1; SMN2HTTMAPTHPGDALDH1A1 | |
| SCHEMBL3499050 | 0.82 | ALDH1A1 (0.34) | SMN1; SMN2HTTKMT2AMAPTHPGD | |
| SCHEMBL2976289 | 0.82 | SMN1; SMN2 (0.33) | SMN1; SMN2HTTKMT2AMAPTNR1H3 | |
| SCHEMBL3499830 | 0.78 | L3MBTL1 (0.32) | SMN1; SMN2HTTMAPTHPGDALDH1A1 | |
| SCHEMBL3498993 | 0.77 | MAPT (0.31) | MAPT | |
| SCHEMBL3500902 | 0.76 | MAPT (0.34) | KMT2AMAPT | |
| SCHEMBL3499064 | 0.76 | NR1H3 (0.31) | NR1H3HPGDALDH1A1LMNA | |
| SCHEMBL3501468 | 0.75 | MEN1 (0.31) | KMT2AMAPT | |
| SCHEMBL3499094 | 0.74 | LMNA (0.32) | HTTMAPTHPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144702-A1 | INDOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144702-A1 | INDOLE COMPOUND | GCKR, GPR119, SLC5A1 | SMN1; SMN2 4708/4885HTT 1610/4885KMT2A 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.